XNAzyme Split Configuration for Rapid Nucleic Acid Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid detection methods, such as qRT-PCR, are slow, require specialized equipment and personnel, and suffer from non-specific DNA amplification issues leading to high false positive rates, limiting their scalability and accuracy in rapid pathogen detection.
Innovation Solution
A multicomponent nucleic acid enzyme (XNAzyme) with a split configuration, derived from DNAzyme 10-23, utilizing nucleic acid analogues for highly specific detection, capable of generating an output signal upon binding to a trigger sequence, allowing for attomolar sensitivity and rapid, accurate monitoring of nucleic acids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If qRT-PCR is used for nucleic acid detection, then detection accuracy is improved, but turnaround time increases and scalability decreases
Solution Approach 1:
The patent replaces the thermal cycling mechanical system of qRT-PCR with an isothermal chemical amplification system using DNAzymes. The DNAzyme-catalyzed cleavage of reporter molecules occurs at constant temperature, eliminating the need for complex thermal cycler equipment while maintaining detection accuracy through specific nucleic acid recognition and catalytic amplification.
Solution Approach 2:
The patent extracts the detection function from complex qRT-PCR systems by using DNAzymes that can be directly added to samples. The DNAzyme-based detection system separates the amplification and detection steps, allowing rapid detection without the time-consuming thermal cycling process, thus reducing turnaround time while preserving measurement precision.
2Loss of time
If isothermal amplification methods (RT-LAMP, RT-RPA) are used, then turnaround time is reduced, but false positive rate increases due to non-specific amplification
Solution Approach 1:
The patent applies local quality by designing DNAzymes with highly specific recognition sequences that bind only to target nucleic acids. The DNAzyme active sites are engineered to recognize specific molecular structures, ensuring that catalysis occurs only when the correct target is present. This localized specificity at the molecular recognition level eliminates non-specific amplification while maintaining rapid isothermal detection.
Solution Approach 2:
The patent replaces enzymatic amplification systems prone to non-specific binding with DNAzyme-based catalytic cleavage. The DNAzymes use precise metal ion coordination and base-pairing recognition mechanisms that are inherently more specific than protein-based enzymes, reducing false positives while maintaining fast turnaround times through isothermal operation.
3Measurement precision
If specialized equipment and trained personnel are used for qRT-PCR, then detection accuracy is improved, but device complexity and operational difficulty increase
Solution Approach 1:
The patent replaces complex thermal cycling equipment with simple isothermal reaction systems. DNAzymes function at constant temperatures (typically 37-50°C), eliminating the need for programmable thermal cyclers. The detection can be performed in simple reaction vessels with basic temperature control, dramatically reducing device complexity while maintaining detection accuracy through the inherent specificity of DNAzyme-nucleic acid interactions.
Solution Approach 2:
The patent implements self-service by designing DNAzyme-based systems that do not require trained personnel for operation. The DNAzymes automatically recognize and bind to target sequences, catalyze reporter cleavage, and generate detectable signals without manual intervention. The reaction conditions are self-optimizing, and results can be read using simple detection methods, making the system accessible to untrained users while maintaining high measurement precision.
4Measurement precision
If CRISPR-based detection is used, then sensitivity is improved, but manufacturing complexity increases due to guide sequence and protein expression requirements
Solution Approach 1:
The patent extracts the detection function from CRISPR systems by using DNAzymes that directly recognize target sequences without requiring guide RNA-Cas protein complexes. The DNAzyme sequences are synthesized as simple oligonucleotides, eliminating the need for complex guide sequence design and recombinant protein expression. This extraction of the core detection function maintains high sensitivity while dramatically simplifying manufacturing.
Solution Approach 2:
The patent uses chemically synthesized DNAzyme oligonucleotides instead of expensive recombinant Cas proteins. The DNAzymes are produced through standard oligonucleotide synthesis, making them inexpensive and easily manufactured. These short-lived synthetic molecules replace the need for stable protein expression systems, simplifying manufacturing while maintaining detection sensitivity through the catalytic activity of the DNAzyme structures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The XNAzyme enables rapid, inexpensive, and accurate detection of nucleic acids, including RNA and DNA, with attomolar sensitivity, reducing false positives and improving scalability for point-of-care diagnostics and genotyping.
Implementation Method 1
The XNAzyme features a split configuration, enabling its function as a sensor capable of generating an output signal in response to the presence of an input trigger sequence (nucleic acid sequence)
Implementation Method 2
Signal amplification via cleavage of a reporter (e.g., nucleic acid reporter) occurs when the XNAzyme is bound to the trigger sequence
Data Source
AI summary
XNAzyme compositions featuring nucleotide analogs, wherein the compositions are capable of rapid, inexpensive, sensitive, and accurate nucleic acid detection. The methods, systems, and compositions herein can provide new options for pathogen detection (e.g., virus detection such as but not limited to SARS-CoV-2), disease diagnosis, and genotyping. The XNAzyme compositions of the present invention combine analyte preamplification with X10-23 mediated catalysis to detect particular nucleic acid trigger sequences. The system functions with a detection limit of at least 20 aM (˜10 copies/μL). With an assay time of less than an hour, the present invention provides a faster alternative to quantitative real-time PCR used for viral detection.